CNBCLean R·
Biotechs buck a sluggish IPO market, but investors should tread warily
While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
Read at CNBC →
Business · 1 sources covering this
Biotechs buck a sluggish IPO market, but investors should tread warily
While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/434820bcc82d1d7faa3c9593c51808f807b12b92" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Biotechs buck a sluggish IPO market, but investors should tread warily"></iframe>
